Scandinavian ChemoTech's subsidiary for Animal Care receives additional orders for TSE treatment kits
Today, ChemoTech's subsidiary for Animal Care in the USA received its first major supplementary order for TSE treatment kits to a value of approximately 17,000 euros. The order shows that the implementation and frequency of use have exceeded expectations, which means that ChemoTech has reason to adjust internal sales forecasts.
In June 2023, ChemoTech's Animal Care division received a large order for several vetIQure™ systems to be delivered in 2023. As previously published, on August 18, it took the customer only two months to complete this order. Today, another supplementary order for TSE treatment kits has been placed, which indicates that the implementation has gone faster, and the frequency of TSE treatments has been higher than previously estimated.
"It is of course satisfying to see that larger customers with great growth potential feel safe and satisfied with our unique TSE treatment. Even if the order value itself is not significant in its size, the high frequency of use signals that we have underestimated what larger specialized animal hospitals can provide in terms of revenue. It is only now that we can really begin to set realistic expectations about how often a larger clinic can imagine performing TSE treatments on cats and dogs”, says Mohan Frick, CEO of ChemoTech and Vetiqure.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB, Phone: +46 (0)8 - 121 576 90
E-mail: certifiedadviser@redeye.se
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-10-2023 17:30 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.